Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

This case report describes a 69-year-old woman who developed drug-induced acquired ichthyosis related to ponatinib therapy, which improved upon stopping the medication.

In this study, researchers examined a patient with ZMYM2::FGFR1 fusion-positive leukemia, finding that Pemigatinib showed efficacy, while Ponatinib resistance was linked to a specific FGFR1 mutation. Other FGFR inhibitors demonstrated high effectiveness in ex vivo assays.

This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.

This study evaluated the real-world safety of Tepotinib for treating NSCLC with METex14 skipping mutations, confirming known adverse events and identifying new signals like deafness and taste disorder, especially highlighting early monitoring.

This case study reports generalized keratosis pilaris as a rare cutaneous side effect of nilotinib in a 40-year-old woman with chronic myeloid leukemia, highlighting the need for awareness among physicians.

This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.

This article describes cutaneous reactions including keratosis pilaris-like eruptions in a patient on nilotinib for chronic myelogenous leukemia, emphasizing the importance of accurately classifying such eruptions.

This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

This study demonstrated that adenosine triphosphate may prevent vandetanib-induced skin toxicity in rats, suggesting potential for further research in other animal models and humans.

This article reviews the use of sorafenib, a multikinase inhibitor, for treating certain carcinomas, noting that cutaneous toxicity during treatment may indicate successful antitumor activity; however, it reports no new clinical results.

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.

This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.

This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

This study reports the case of an elderly patient with a keratosis pilaris-like skin eruption after beginning treatment with imatinib for chronic myeloid leukemia, discussing similar skin reactions to BCR-ABL inhibitors and exploring potential mechanisms behind these adverse cutaneous reactions.

Nilotinib may cause gray hair to return to its original color.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

This review examined the common side effects of FGFR inhibitors like erdafitinib, pemigatinib, and futibatinib, and detailed strategies for managing them, highlighting that proactive monitoring and appropriate interventions can effectively mitigate these toxicities.

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.